Published in Cancer Prev Res (Phila) on December 12, 2011
MicroRNA profiling: approaches and considerations. Nat Rev Genet (2012) 4.39
Standardization of sample collection, isolation and analysis methods in extracellular vesicle research. J Extracell Vesicles (2013) 4.05
Extracellular vesicle-mediated transfer of genetic information between the hematopoietic system and the brain in response to inflammation. PLoS Biol (2014) 3.46
Clinical utility of a plasma-based miRNA signature classifier within computed tomography lung cancer screening: a correlative MILD trial study. J Clin Oncol (2014) 2.57
Prognostic value of miR-155 in individuals with monoclonal B-cell lymphocytosis and patients with B chronic lymphocytic leukemia. Blood (2013) 1.87
Comprehensive profiling of circulating microRNA via small RNA sequencing of cDNA libraries reveals biomarker potential and limitations. Proc Natl Acad Sci U S A (2013) 1.79
MicroRNAs as potential biomarkers in human solid tumors. Cancer Lett (2012) 1.73
Plasma processing conditions substantially influence circulating microRNA biomarker levels. PLoS One (2013) 1.71
Identification of the long non-coding RNA H19 in plasma as a novel biomarker for diagnosis of gastric cancer. Sci Rep (2015) 1.55
Circulating miRNAs: cell-cell communication function? Front Genet (2013) 1.55
The Impact of Hemolysis on Cell-Free microRNA Biomarkers. Front Genet (2013) 1.54
Identification of the long non-coding RNA POU3F3 in plasma as a novel biomarker for diagnosis of esophageal squamous cell carcinoma. Mol Cancer (2015) 1.51
A small noncoding RNA signature found in exosomes of GBM patient serum as a diagnostic tool. Neuro Oncol (2014) 1.40
Retracted Risk miRNA screening of ovarian cancer based on miRNA functional synergistic network. J Ovarian Res (2014) 1.40
Clinical impact of circulating miR-221 in plasma of patients with pancreatic cancer. Br J Cancer (2013) 1.39
Distinct AGO1 and AGO2 associated miRNA profiles in human cells and blood plasma. RNA Biol (2012) 1.38
Cell-free Circulating miRNA Biomarkers in Cancer. J Cancer (2012) 1.37
Dampening enthusiasm for circulating microRNA in breast cancer. PLoS One (2013) 1.37
A critical evaluation of microRNA biomarkers in non-neoplastic disease. PLoS One (2014) 1.35
Lessons from miR-143/145: the importance of cell-type localization of miRNAs. Nucleic Acids Res (2014) 1.34
Serum microRNA-155 as a potential biomarker to track disease in breast cancer. PLoS One (2012) 1.33
Circulating microRNA profiles in human patients with acetaminophen hepatotoxicity or ischemic hepatitis. Proc Natl Acad Sci U S A (2014) 1.32
Circulating miR-200c as a diagnostic and prognostic biomarker for gastric cancer. J Transl Med (2012) 1.31
In vivo delivery of miRNAs for cancer therapy: challenges and strategies. Adv Drug Deliv Rev (2014) 1.28
Circulating microRNAs predict biochemical recurrence in prostate cancer patients. Br J Cancer (2013) 1.25
Method for microRNA isolation from clinical serum samples. Anal Biochem (2012) 1.23
Comparison of Methods for miRNA Extraction from Plasma and Quantitative Recovery of RNA from Cerebrospinal Fluid. Front Genet (2013) 1.23
Circulating biomarkers for detection of ovarian cancer and predicting cancer outcomes. Br J Cancer (2013) 1.21
Circulating miR-378 in plasma: a reliable, haemolysis-independent biomarker for colorectal cancer. Br J Cancer (2014) 1.19
Comparisons of microRNA patterns in plasma before and after tumor removal reveal new biomarkers of lung squamous cell carcinoma. PLoS One (2013) 1.17
Extracellular communication via microRNA: lipid particles have a new message. J Lipid Res (2013) 1.17
Genome-wide sequencing of cellular microRNAs identifies a combinatorial expression signature diagnostic of sepsis. PLoS One (2013) 1.15
MicroRNA expression profiles of whole blood in lung adenocarcinoma. PLoS One (2012) 1.13
Exosomal and Non-Exosomal Transport of Extra-Cellular microRNAs in Follicular Fluid: Implications for Bovine Oocyte Developmental Competence. PLoS One (2013) 1.13
DNA methylation and microRNA biomarkers for noninvasive detection of gastric and colorectal cancer. Biochem Biophys Res Commun (2014) 1.12
Extracellular microRNAs in urologic malignancies: chances and challenges. Int J Mol Sci (2013) 1.11
Challenges in using circulating miRNAs as cancer biomarkers. Biomed Res Int (2015) 1.08
Absolute quantification of cell-free microRNAs in cancer patients. Oncotarget (2015) 1.08
Principal component analysis based feature extraction approach to identify circulating microRNA biomarkers. PLoS One (2013) 1.08
Identification of sensitive serum microRNA biomarkers for radiation biodosimetry. PLoS One (2013) 1.07
MicroRNAs: new players in IBD. Gut (2014) 1.07
Profiles of extracellular miRNA in cerebrospinal fluid and serum from patients with Alzheimer's and Parkinson's diseases correlate with disease status and features of pathology. PLoS One (2014) 1.07
Exosomal miRNAs as Biomarkers for Prostate Cancer. Front Genet (2013) 1.06
Circulating inflamma-miRs in aging and age-related diseases. Front Genet (2013) 1.06
Clinical impact of circulating miR-18a in plasma of patients with oesophageal squamous cell carcinoma. Br J Cancer (2013) 1.05
Circulating cell-free microRNA as biomarkers for screening, diagnosis and monitoring of neurodegenerative diseases and other neurologic pathologies. Front Cell Neurosci (2013) 1.04
Plasma microRNA profiles: identification of miR-25 as a novel diagnostic and monitoring biomarker in oesophageal squamous cell carcinoma. Br J Cancer (2014) 1.04
Distinctive serum miRNA profile in mouse models of striated muscular pathologies. PLoS One (2013) 1.03
The emerging role of miRNAs in inflammatory bowel disease: a review. Therap Adv Gastroenterol (2015) 1.03
Meeting report: discussions and preliminary findings on extracellular RNA measurement methods from laboratories in the NIH Extracellular RNA Communication Consortium. J Extracell Vesicles (2015) 1.02
A Novel Serum 4-microRNA Signature for Lung Cancer Detection. Sci Rep (2015) 1.02
XenomiRs and miRNA homeostasis in health and disease: evidence that diet and dietary miRNAs directly and indirectly influence circulating miRNA profiles. RNA Biol (2012) 1.02
Circulating miR-148b and miR-133a as biomarkers for breast cancer detection. Oncotarget (2014) 1.02
Circulating miR-18a in plasma contributes to cancer detection and monitoring in patients with gastric cancer. Gastric Cancer (2014) 1.01
Design and Analysis for Studying microRNAs in Human Disease: A Primer on -Omic Technologies. Am J Epidemiol (2014) 1.00
MicroRNAs in skeletal muscle and their regulation with exercise, ageing, and disease. Front Physiol (2013) 1.00
Regulation of miRNA biogenesis and turnover in the immune system. Immunol Rev (2013) 1.00
Plasma microRNA panel for minimally invasive detection of breast cancer. PLoS One (2013) 0.99
Identification and validation of miRNAs as endogenous controls for RQ-PCR in blood specimens for breast cancer studies. PLoS One (2013) 0.99
Pre-profiling factors influencing serum microRNA levels. BMC Clin Pathol (2014) 0.99
Normalization of circulating microRNA expression data obtained by quantitative real-time RT-PCR. Brief Bioinform (2015) 0.98
Sensitive PCR-based quantitation of cell-free circulating microRNAs. Methods (2012) 0.98
Circulating MicroRNAs as Non-Invasive Biomarkers for Early Detection of Non-Small-Cell Lung Cancer. PLoS One (2015) 0.97
Cell-free microRNAs: potential biomarkers in need of standardized reporting. Front Genet (2013) 0.97
Comparison of different extraction techniques to profile microRNAs from human sera and peripheral blood mononuclear cells. BMC Genomics (2014) 0.97
Quantification of Plasma miRNAs by Digital PCR for Cancer Diagnosis. Biomark Insights (2013) 0.96
Determination of 14 circulating microRNAs in Swedes and Iraqis with and without diabetes mellitus type 2. PLoS One (2014) 0.95
Detection of circulating parasite-derived microRNAs in filarial infections. PLoS Negl Trop Dis (2014) 0.95
Comparison of a healthy miRNome with melanoma patient miRNomes: are microRNAs suitable serum biomarkers for cancer? Oncotarget (2015) 0.95
Long non-coding RNA HULC as a novel serum biomarker for diagnosis and prognosis prediction of gastric cancer. Oncotarget (2016) 0.95
Different miRNA expression profiles between human breast cancer tumors and serum. Front Genet (2014) 0.94
Breast Cancer-Specific miR Signature Unique to Extracellular Vesicles Includes "microRNA-like" tRNA Fragments. Mol Cancer Res (2015) 0.93
High serum miR-19a levels are associated with inflammatory breast cancer and are predictive of favorable clinical outcome in patients with metastatic HER2+ inflammatory breast cancer. PLoS One (2014) 0.93
Epstein-Barr Virus MicroRNAs are Expressed in Patients with Chronic Lymphocytic Leukemia and Correlate with Overall Survival. EBioMedicine (2015) 0.92
Identification of circulating microRNAs for the differential diagnosis of Parkinson's disease and Multiple System Atrophy. Front Cell Neurosci (2014) 0.92
MicroRNA molecular profiling from matched tumor and bio-fluids in bladder cancer. Mol Cancer (2015) 0.92
Optimization of extraction of circulating RNAs from plasma--enabling small RNA sequencing. PLoS One (2014) 0.91
Circulating microRNAs as diagnostic and prognostic tools for hepatocellular carcinoma. World J Gastroenterol (2015) 0.90
Circulating microRNAs as biomarkers for inflammatory diseases. Microrna (2013) 0.90
Technical factors involved in the measurement of circulating microRNA biomarkers for the detection of colorectal neoplasia. PLoS One (2014) 0.90
Comparison of circulating, hepatocyte specific messenger RNA and microRNA as biomarkers for chronic hepatitis B and C. PLoS One (2014) 0.89
MicroRNA expression differences in human hematopoietic cell lineages enable regulated transgene expression. PLoS One (2014) 0.89
MicroRNA profiling of pericardial fluid samples from patients with heart failure. PLoS One (2015) 0.88
Circulating cell-free microRNAs as biomarkers for colorectal cancer. Surg Today (2015) 0.88
Circulating long non-coding RNAs in cancer: current status and future perspectives. Mol Cancer (2016) 0.88
A Five-miRNA Panel Identified From a Multicentric Case-control Study Serves as a Novel Diagnostic Tool for Ethnically Diverse Non-small-cell Lung Cancer Patients. EBioMedicine (2015) 0.88
Extracellular microRNAs as Biomarkers in Human Disease. Chonnam Med J (2015) 0.88
Maternal and neonatal plasma microRNA biomarkers for fetal alcohol exposure in an ovine model. Alcohol Clin Exp Res (2014) 0.87
Examining plasma microRNA markers for colorectal cancer at different stages. Oncotarget (2016) 0.86
New Concepts in Cancer Biomarkers: Circulating miRNAs in Liquid Biopsies. Int J Mol Sci (2016) 0.86
Liquid biopsy of gastric cancer patients: circulating tumor cells and cell-free nucleic acids. World J Gastroenterol (2014) 0.86
Associations of circulating plasma microRNAs with age, body mass index and sex in a population-based study. BMC Med Genomics (2015) 0.86
Circulating miRNAs miR-34a and miR-150 associated with colorectal cancer progression. BMC Cancer (2015) 0.86
Tissue-specific and plasma microRNA profiles could be promising biomarkers of histological classification and TNM stage in non-small cell lung cancer. Thorac Cancer (2016) 0.85
Elevated serum microRNA levels associate with absence of high-grade prostate cancer in a retrospective cohort. PLoS One (2015) 0.85
Non-Coding RNAs in Primary Liver Cancer. Front Med (Lausanne) (2015) 0.85
The biology of circulating microRNAs in cardiovascular disease. Eur J Clin Invest (2015) 0.85
Serum microRNAs in HIV-infected individuals as pre-diagnosis biomarkers for AIDS-NHL. J Acquir Immune Defic Syndr (2014) 0.85
High-throughput qRT-PCR validation of blood microRNAs in non-small cell lung cancer. Oncotarget (2016) 0.85
The circulating transcriptome as a source of non-invasive cancer biomarkers: concepts and controversies of non-coding and coding RNA in body fluids. J Cell Mol Med (2015) 0.85
Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci U S A (2008) 33.65
Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases. Cell Res (2008) 20.59
MicroRNA signatures of tumor-derived exosomes as diagnostic biomarkers of ovarian cancer. Gynecol Oncol (2008) 11.46
Argonaute2 complexes carry a population of circulating microRNAs independent of vesicles in human plasma. Proc Natl Acad Sci U S A (2011) 10.56
Detection of elevated levels of tumour-associated microRNAs in serum of patients with diffuse large B-cell lymphoma. Br J Haematol (2008) 10.28
Differential expression of microRNAs in plasma of patients with colorectal cancer: a potential marker for colorectal cancer screening. Gut (2009) 8.98
Detection and characterization of placental microRNAs in maternal plasma. Clin Chem (2008) 6.40
Analysis of circulating microRNA biomarkers in plasma and serum using quantitative reverse transcription-PCR (qRT-PCR). Methods (2010) 6.25
Serum microRNA signatures identified in a genome-wide serum microRNA expression profiling predict survival of non-small-cell lung cancer. J Clin Oncol (2010) 5.92
Plasma microRNAs are promising novel biomarkers for early detection of colorectal cancer. Int J Cancer (2010) 5.57
Circulating microRNA in body fluid: a new potential biomarker for cancer diagnosis and prognosis. Cancer Sci (2010) 5.17
Circulating microRNAs as novel minimally invasive biomarkers for breast cancer. Ann Surg (2010) 4.59
MicroRNA signatures in tissues and plasma predict development and prognosis of computed tomography detected lung cancer. Proc Natl Acad Sci U S A (2011) 4.11
Circulating microRNAs in plasma of patients with gastric cancers. Br J Cancer (2010) 3.59
MicroRNAs in plasma of pancreatic ductal adenocarcinoma patients as novel blood-based biomarkers of disease. Cancer Prev Res (Phila) (2009) 3.55
Circulating microRNAs, miR-21, miR-122, and miR-223, in patients with hepatocellular carcinoma or chronic hepatitis. Mol Carcinog (2010) 3.44
Analysis of circulating microRNA: preanalytical and analytical challenges. Clin Chem (2011) 3.15
Circulating miRNAs are correlated with tumor progression in prostate cancer. Int J Cancer (2011) 3.02
Usefulness of the neutrophil-to-lymphocyte ratio in predicting short- and long-term mortality in breast cancer patients. Ann Surg Oncol (2011) 2.89
Plasma microRNA-122 as a biomarker for viral-, alcohol-, and chemical-related hepatic diseases. Clin Chem (2010) 2.86
Circulating microRNAs in breast cancer and healthy subjects. BMC Res Notes (2009) 2.78
Detection of cancer with serum miRNAs on an oligonucleotide microarray. PLoS One (2009) 2.68
A pilot study of circulating miRNAs as potential biomarkers of early stage breast cancer. PLoS One (2010) 2.64
Pretreatment neutrophil count as an independent prognostic factor in advanced non-small-cell lung cancer: an analysis of Japan Multinational Trial Organisation LC00-03. Eur J Cancer (2009) 2.35
Expression profile of microRNAs in serum: a fingerprint for esophageal squamous cell carcinoma. Clin Chem (2010) 2.34
Impact of cellular miRNAs on circulating miRNA biomarker signatures. PLoS One (2011) 2.24
Serum microRNAs as powerful cancer biomarkers. Biochim Biophys Acta (2010) 1.98
Microfluidic-based multiplex qRT-PCR identifies diagnostic and prognostic microRNA signatures in the sera of prostate cancer patients. Cancer Res (2010) 1.89
Differentially expressed miRNAs in the plasma may provide a molecular signature for aggressive pancreatic cancer. Am J Transl Res (2010) 1.74
Circulating miRNA signatures: promising prognostic tools for cancer. J Clin Oncol (2010) 1.20
Advanced oxidation protein products and total antioxidant activity in colorectal carcinoma. Indian J Physiol Pharmacol (2010) 0.91
Biallelic Inactivation of BRCA2 in Platinum-sensitive Metastatic Castration-resistant Prostate Cancer. Eur Urol (2015) 0.93
Genetic features of myelodysplastic syndrome and aplastic anemia in pediatric and young adult patients. Haematologica (2016) 0.83
DNA Repair in Prostate Cancer: Biology and Clinical Implications. Eur Urol (2016) 0.77
Mismatch repair deficiency may be common in ductal adenocarcinoma of the prostate. Oncotarget (2016) 0.75
Family-Specific Variants and the Limits of Human Genetics. Trends Mol Med (2016) 0.75